Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918568 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL27932371 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL22661725 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL918791 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL1685684 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29549533 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL30403231 | 0.86 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29001613 | 0.86 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12116904 | 0.80 | NPC1 (0.38) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL20500207 | 0.79 | NPC1 (0.40) | NPC1MEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | NPC1 1038/4885MEN1 1152/4885KMT2A 3169/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | NPC1 1038/4885MEN1 1152/4885KMT2A 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.